A Phase I/II Study of Nivolumab Plus or Minus Ipilimumab in Combination with Multi-Fraction Stereotactic Radiosurgery for Recurrent High-Grade Radiation-Relapsed Meningioma
Details
A Phase I/II Study of Nivolumab plus or minus Ipilimumab in Combination with Multi-fraction Stereotactic Radiosurgery for Recurrent High-grade Radiation-relapsed Meningioma
Eligibility
You can join if...
Inclusion Criteria:
Patients must have histologically confirmed WHO grade II-III meningioma which has relapsed after prior radiation therapy with radiologically progressive or recurrent disease.
Age >18
Ability to understand and the willingness to sign a written informed consent document or, if decision-making capacity is impaired, consent of a legally authorized representative (e.g., spouse, adult child, live-in caretaker).
Exclusion Criteria:
-Patients who have had chemotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study
Patients who have had radiation therapy (to the site of reirradiation) within 6 months prior to entering the study
History of severe hypersensitivity reaction to any monoclonal antibody